July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Bi-functional small molecule for glaucomatous optic neuropathy
Author Affiliations & Notes
  • Suchismita Acharya
    Department of Pharmacology and Neuroscience, UNT Health Science Center, Fort Worth, Texas, United States
    North Tx Eye Research Institute, UNT Health Science Center, Fort Worth, Texas, United States
  • Dorota L Stankowska
    Department of Pharmacology and Neuroscience, UNT Health Science Center, Fort Worth, Texas, United States
    North Tx Eye Research Institute, UNT Health Science Center, Fort Worth, Texas, United States
  • Renuka Makarand Chaphalkar
    Department of Pharmacology and Neuroscience, UNT Health Science Center, Fort Worth, Texas, United States
    North Tx Eye Research Institute, UNT Health Science Center, Fort Worth, Texas, United States
  • Linya Li
    Department of Pharmacology and Neuroscience, UNT Health Science Center, Fort Worth, Texas, United States
    North Tx Eye Research Institute, UNT Health Science Center, Fort Worth, Texas, United States
  • Dorette Z Ellis
    North Tx Eye Research Institute, UNT Health Science Center, Fort Worth, Texas, United States
  • Kytai T Nguyen
    Department of Bioengineering, The University of Texas at Arlington, Arlington, Texas, United States
  • Thomas Yorio
    Department of Pharmacology and Neuroscience, UNT Health Science Center, Fort Worth, Texas, United States
    North Tx Eye Research Institute, UNT Health Science Center, Fort Worth, Texas, United States
  • Footnotes
    Commercial Relationships   Suchismita Acharya, None; Dorota Stankowska, None; Renuka Chaphalkar, None; Linya Li, None; Dorette Ellis, None; Kytai Nguyen, None; Thomas Yorio, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 5298. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Suchismita Acharya, Dorota L Stankowska, Renuka Makarand Chaphalkar, Linya Li, Dorette Z Ellis, Kytai T Nguyen, Thomas Yorio; Bi-functional small molecule for glaucomatous optic neuropathy. Invest. Ophthalmol. Vis. Sci. 2018;59(9):5298.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The multifaceted pathology associated with glaucoma is difficult to treat by monotherapy such as lowering intraocular pressure (IOP). Oxidative stress is involved in IOP elevation and retinal ganglion cell (RGC) death possibly via decreased activity of antioxidant enzymes. Our hypothesis is that, a small hybrid molecule SA-2 and its PLGA encapsulated nanoparticle (NP) drug delivery vehicle (SA-2-NPs) possessing a nitric oxide (NO) donating group and a redox antioxidant moiety will lower IOP as well as possess neuro/cytoprotective potential.

Methods : IOP-independent neuroprotection of RGCs: Mice (C57BL6, 12 weeks, n=5) were anesthetized and the optic nerve crush (ONC) was performed on one eye followed by intravitreal injection of 2ml of 1% SA-2 formulated in PBS or vehicle to the crushed eye at day 0 and 3. At day 7, pattern electroretinogram (PERG) was performed, following which retinas were flat mounted. Number of surviving, RBPMS positive RGCs were counted. IOP lowering effect: Nine Brown Norway normotensive rats (n=3 per each group) were used to evaluate the IOP-lowering properties of SA-2-NPs under a masked protocol. Topical eye drops (30 µL/drop) containing : A) Vehicle (PBS), B) Travoprost (0.004%)-positive control or C) SA-2-NPs (100 µg/mL) formulated in PBS were administered in three rats and IOP was measured using the TonoLab rebound tonometer at various time points: 0, 3, 6, 24 and 48 h post-dosing. The entire dosing schedule was repeated 3 times in each rat.

Results : Compound SA-2 treatment was significantly (p<0.001, t-test) protecting against RGCs loss following ONC. Number of RGCs for ONC and PBS treated mice was 1000 cells/cm2 vs ONC and SA-2 treated group (2100 cells/cm2) and was comparable to the naïve control (2650 cells/cm2), (n = 3 or 4 animals per group). PLGA encapsulated SA-2-NPs (100mg) statistically (t-test, p<0.001) lowered the IOP in treated eyes by 19% and 21% at 24 and 48h respectively in comparison to contralateral control eyes. Travoprost was statistically effective in lowering IOP in treated rat eye by 14% at 6h.

Conclusions : Taken together, our results are consistent with our hypothesis that this novel class of hybrid compound and its PLGA encapsulated nanoparticle will decrease IOP and protect RGCs from cell death. Further structure optimization of the lead compound, dose optimization, IOP lowering study in ocular hypertensive rodent models are underway.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×